tirzepatide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Despite the side effects associated with tirzepatide, the RR for serious adverse events with once‐weekly tirzepatide compared with placebo was 0.93 (95% CI: 0.76–1.13, p = 0.45), which was not statistically significant.”
Quoted verbatim from Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg or maximum tolerated dose, once weekly
- Population
- Adults with overweight or obesity without diabetes, six placebo-controlled randomised trials
Effect 0.93 risk ratio, 95% CI 0.76 to 1.13
Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:40510020Permalink
Keep reading
- Everything the graph holds on tirzepatide
- Every compound studied against Serious adverse event incidence
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45MMXJV5VEJKGW7AHW38JTR